title: Phenotypic changes in neutrophils related to anti-inflammatory therapy.
abstract: Previous work from the group has shown that non-steroidal anti-inflammatory agents given to volunteers and patients inhibit PMN function possibly by affecting the developing neutrophil during the differentiation process. In this study indomethacin treatment in vivo reduced neutrophil chemotaxis and proteolytic degradation of fibronectin, with a maximal effect after 14 days. Stimulated neutrophil adherence to fibronectin was also reduced but this was not due to quantitative changes in beta(2) integrin expression or function. L-Selectin expression on resting and stimulated neutrophils was increased after 14 days and there was a small decrease in plasma levels of soluble L-selectin. These effects, however, could not be reproduced by treatment of neutrophils with indomethacin in vitro, suggesting they are due to effects on differentiating/maturing PMNs. In an attempt to interpret these changes, studies were performed with dexamethasone, which is known to alter neutrophil function and kinetics. Dexamethasone treatment reduced chemotaxis and increased superoxide generation after 1 day and was associated with increased expression of activated beta(2) integrins and reduced L-selectin expression on resting neutrophils. This suggests the appearance of mainly 'activated' cells as a result of demargination and indicates that the effects of indomethacin are distinctive and not related to changes in compartmentalisation.
authors.affiliation: Respiratory Research Laboratory, Department of Medicine, The Queen Elizabeth Hospital, Edgbaston, Birmingham, UK.
authors.forename: A E
authors.initials: AE
authors.lastname: Barton
authors.forename: D L
authors.initials: DL
authors.lastname: Bayley
authors.forename: M
authors.initials: M
authors.lastname: Mikami
authors.forename: C G
authors.initials: CG
authors.lastname: Llewellyn-Jones
authors.forename: R A
authors.initials: RA
authors.lastname: Stockley
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D015703:Antigens, CD / Q000378:metabolism; D018821:CD18 Antigens / Q000096:biosynthesis; D002454:Cell Differentiation / Q000187:drug effects; D002478:Cells, Cultured; D002633:Chemotaxis / Q000187:drug effects; D003907:Dexamethasone / Q000494:pharmacology; D015194:Diffusion Chambers, Culture; D005260:Female; D005353:Fibronectins / Q000378:metabolism; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology*; D016209:Interleukin-8 / Q000494:pharmacology; D019041:L-Selectin / Q000096:biosynthesis / Q000097:blood; D008297:Male; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000166:cytology* / Q000187:drug effects*; D010641:Phenotype
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D015703:Antigens, CD; D018821:CD18 Antigens; D005353:Fibronectins; D016209:Interleukin-8; D019041:L-Selectin; D009240:N-Formylmethionine Leucyl-Phenylalanine; D003907:Dexamethasone; D007213:Indomethacin